Triple-Action antibody takes aim at advanced breast cancer
NCT ID NCT07738341
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is to see if the drug is safe, tolerable, and effective at shrinking tumors. The study includes multiple groups based on breast cancer subtype and prior treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB268, a tri-specific antibody targeting PD-1, CTLA-4, and VEGF, given alone or with chemotherapy or antibody-drug conjugates
- What this could lead to
- If it works, this could offer a new treatment option for advanced breast cancer, potentially shrinking tumors and extending life.
- What could go wrong
- This is an early-stage trial, so the drug may not work or may cause side effects. Results are preliminary and need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tiny drug particles aim to shrink breast tumors
- New drug INV-6452 targets Hard-to-Treat breast cancers
- AI phone app aims to ease cancer treatment side effects
- New study aims to sharpen detection of breast cancer metastases
- Engineered immune cells take on Hard-to-Treat breast cancers
- Tattoo marks could help surgeons save more breasts in cancer fight